UBS Group AG Boosts Stock Holdings in Maximus, Inc. $MMS

Posted by Francis Steltz on May 6th, 2026

UBS Group AG raised its position in Maximus, Inc. (NYSE:MMS – Free Report) by 76.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 610,354 shares of the health services provider’s stock after purchasing an additional 265,095 shares during the period. UBS Group AG’s holdings in Maximus were worth $52,686,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of MMS. Farther Finance Advisors LLC raised its holdings in shares of Maximus by 69.0% in the 4th quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider’s stock valued at $25,000 after purchasing an additional 116 shares in the last quarter. Richardson Financial Services Inc. raised its holdings in shares of Maximus by 123.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 348 shares of the health services provider’s stock valued at $32,000 after purchasing an additional 192 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Maximus in the 3rd quarter valued at $32,000. Canada Pension Plan Investment Board acquired a new stake in shares of Maximus in the 2nd quarter valued at $35,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Maximus in the 3rd quarter valued at $38,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

Maximus Trading Up 1.2%

NYSE:MMS opened at $65.29 on Wednesday. The company has a market capitalization of $3.56 billion, a PE ratio of 9.94 and a beta of 0.60. Maximus, Inc. has a 52-week low of $60.75 and a 52-week high of $100.00. The stock’s 50 day moving average price is $69.11 and its 200 day moving average price is $80.28. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88.

Maximus (NYSE:MMS – Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 EPS for the quarter, topping the consensus estimate of $1.84 by $0.01. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.37 billion. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The firm’s revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, research analysts anticipate that Maximus, Inc. will post 8.46 EPS for the current year.

Maximus Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a dividend of $0.33 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.32 annualized dividend and a yield of 2.0%. Maximus’s payout ratio is 20.09%.

Insiders Place Their Bets

In other Maximus news, Director Jan Madsen sold 742 shares of Maximus stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total transaction of $53,609.50. Following the transaction, the director owned 20,795 shares of the company’s stock, valued at $1,502,438.75. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce Caswell purchased 3,175 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were bought at an average cost of $78.45 per share, for a total transaction of $249,078.75. Following the acquisition, the chief executive officer owned 328,013 shares of the company’s stock, valued at approximately $25,732,619.85. The trade was a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MMS shares. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Finally, Weiss Ratings lowered shares of Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Maximus currently has an average rating of “Hold”.

Get Our Latest Stock Analysis on Maximus

Maximus Company Profile

(Free Report)

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.